Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS. Issue 3 (May 2020) - Novi, Giovanni; Ivaldi, Federico; Sbragia, Elvira; Mikulska, Malgorzata; Pesce, Giampaola; Inglese, Matilde; Kerlero de Rosbo, Nicole; Uccelli, Antonio